Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
WUXI BIO Teams up with Candid Therapeutics on T-Cell Engager Trispecific Antibody Research Services
Recommend 7 Positive 12 Negative 5 |
||||
|
||||
|
WUXI BIO (02269.HK) announced that it had inked a research service collaboration agreement with Candid Therapeutics. Under the agreement, Candid Therapeutics will hold global rights to a preclinical trispecific antibody discovered at WUXI BIO's proprietary universal multispecific antibody platform WuXiBody. WUXI BIO will receive an upfront payment and is eligible for development and sales milestone payments, totaling up to US$925 million, along with royalties on product sales post-launch. AAStocks Financial News |
||||
Copied to Clipboard
 |
||||
